Skip to main content
. Author manuscript; available in PMC: 2014 Dec 29.
Published in final edited form as: Radiother Oncol. 2014 Apr 29;111(1):88–93. doi: 10.1016/j.radonc.2014.02.010

Fig. 3.

Fig. 3

Axitinib pre-treatment enables complete responses in radioresistant B16F1 melanomas after SDRT. Sv129/BL6 mice with B16F1 flank tumors were given axitinib 1 h prior to 40 Gy SDRT to the tumor. Arrows denote day of treatment. Lines represent individual tumor responses for each mouse with complete responses in black.